Advertisement

Current Osteoporosis Reports

, Volume 16, Issue 5, pp 596–602 | Cite as

Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy

  • D. Brooke Widner
  • Sun H. Park
  • Matthew R. Eber
  • Yusuke ShiozawaEmail author
Cancer-induced Musculoskeletal Diseases (J Sterling and E Keller, Section Editors)
  • 273 Downloads
Part of the following topical collections:
  1. Topical Collection on Cancer-induced Musculoskeletal Diseases

Abstract

Purpose of Review

To succinctly summarize recent findings concerning dormancy regulating interactions between bone marrow stromal cells and disseminated tumor cells.

Recent Findings

Recent studies have highlighted roles of the bone marrow microenviroment, including osteoblasts, mesenchymal stem cells (MSCs), and endothelial cells, in inducing or maintaining cancer cell dormancy. Key pathways of interest include: osteoblast-induced transforming growth factor (TGF)-β2 signaling, transfer of MSC-derived exosomes containing dormancy inducing microRNA, cancer cell cannibalism of MSCs, and endothelial cell secretion of thrombospondin 1 (TSP1).

Summary

The bone marrow is a common site of metastatic disease recurrence following a period of cancer cell dormancy. Understanding why disseminated tumor cells enter into dormancy and later resume cell proliferation and growth is vital to developing effective therapeutics against these cells. The bone marrow stroma and the various pathways through which it participates in crosstalk with cancer cells are essential to furthering understanding of how dormancy is regulated.

Keywords

Cancer cell dormancy Bone marrow microenviroment Bone marrow stromal cells Osteoblasts Mesenchymal stem cells Endothelial cells 

Notes

Funding

This work is directly supported by Department of Defense (W81XWH-14-1-0403, Y. Shiozawa; W81XWH-17-1-0541, Y. Shiozawa), the Wake Forest Baptist Comprehensive Cancer Center Internal Pilot Funding (Y. Shiozawa), and the Wake Forest School of Medicine Internal Pilot Funding (Y. Shiozawa). Y Shiozawa is supported as the Translational Research Academy which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001420. This work is also supported by the National Cancer Institute’s Cancer Center Support Grant award number P30CA012197 issued to the Wake Forest Baptist Comprehensive Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

Compliance with Ethical Standards

Conflict of Interest

D. Brooke Widner, Sun H. Park, Matthew R. Eber, and Yusuke Shiozawa declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gomis RR, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2016;11:62–78.  https://doi.org/10.1016/j.molonc.2016.09.009.CrossRefGoogle Scholar
  2. 2.
    Gao XL, Zhang M, Tang YL, Liang XH. Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis. Onco Targets Ther. 2017;10:5219–28.  https://doi.org/10.2147/OTT.S140854.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    van der Toom EE, Verdone JE, Pienta KJ. Disseminated tumor cells and dormancy in prostate cancer metastasis. Curr Opin Biotechnol. 2016;40:9–15.  https://doi.org/10.1016/j.copbio.2016.02.002.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Graham N, Qian BZ. Mesenchymal stromal cells: emerging roles in bone metastasis. Int J Mol Sci. 2018;19(4)  https://doi.org/10.3390/ijms19041121.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Marx V. How to pull the blanket off dormant cancer cells. Nat Methods. 2018;15(4):249–52.  https://doi.org/10.1038/nmeth.4640.CrossRefPubMedGoogle Scholar
  6. 6.
    Linde N, Fluegen G, Aguirre-Ghiso JA. The relationship between dormant Cancer cells and their microenvironment. Adv Cancer Res. 2016;132:45–71.  https://doi.org/10.1016/bs.acr.2016.07.002.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gay LJ, Malanchi I. The sleeping ugly: tumour microenvironment's act to make or break the spell of dormancy. Biochim Biophys Acta. 2017;1868(1):231–8.  https://doi.org/10.1016/j.bbcan.2017.05.002.CrossRefGoogle Scholar
  8. 8.
    Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611–22.  https://doi.org/10.1038/nrc3793.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yeh AC, Ramaswamy S. Mechanisms of Cancer cell dormancy--another Hallmark of Cancer? Cancer Res. 2015;75(23):5014–22.  https://doi.org/10.1158/0008-5472.CAN-15-1370.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Senft D, Ronai ZA. Immunogenic, cellular, and angiogenic drivers of tumor dormancy--a melanoma view. Pigment Cell Melanoma Res. 2016;29(1):27–42.  https://doi.org/10.1111/pcmr.12432.CrossRefPubMedGoogle Scholar
  11. 11.
    Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol. 2017;44:72–82.  https://doi.org/10.1016/j.semcancer.2017.03.006.CrossRefPubMedGoogle Scholar
  12. 12.
    • Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH (2018) Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway. Cancer Res.  https://doi.org/10.1158/0008-5472.CAN-17-1051. Paper introduces a new signaling pathway for osteoblast-secreted factors to induce dormancy. CrossRefPubMedGoogle Scholar
  13. 13.
    •• Bartosh TJ, Ullah M, Zeitouni S, Beaver J, Prockop DJ. Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs). Proc Natl Acad Sci U S A. 2016;113(42):E6447–56.  https://doi.org/10.1073/pnas.1612290113. Paper introduces a new signaling pathway for osteoblast-secreted factors to induce dormancy. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Decker AM, Jung Y, Cackowski FC, Yumoto K, Wang J, Taichman RS. Sympathetic signaling reactivates quiescent disseminated prostate Cancer cells in the bone marrow. Mol Cancer Res. 2017;15(12):1644–55.  https://doi.org/10.1158/1541-7786.MCR-17-0132.CrossRefPubMedGoogle Scholar
  15. 15.
    Bliss SA, Sinha G, Sandiford OA, Williams LM, Engelberth DJ, Guiro K, et al. Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast Cancer dormancy in bone marrow. Cancer Res. 2016;76(19):5832–44.  https://doi.org/10.1158/0008-5472.CAN-16-1092.CrossRefPubMedGoogle Scholar
  16. 16.
    Wu JY, Scadden DT, Kronenberg HM. Role of the osteoblast lineage in the bone marrow hematopoietic niches. J Bone Miner Res. 2009;24(5):759–64.  https://doi.org/10.1359/jbmr.090225.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Neiva K, Sun YX, Taichman RS. The role of osteoblasts in regulating hematopoietic stem cell activity and tumor metastasis. Braz J Med Biol Res. 2005;38(10):1449–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Taichman RS, Emerson SG. The role of osteoblasts in the hematopoietic microenvironment. Stem Cells. 1998;16(1):7–15.  https://doi.org/10.1002/stem.160007.CrossRefPubMedGoogle Scholar
  19. 19.
    Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6(2):93–106.  https://doi.org/10.1038/nri1779.CrossRefPubMedGoogle Scholar
  20. 20.
    Yin T, Li L. The stem cell niches in bone. J Clin Invest. 2006;116(5):1195–201.  https://doi.org/10.1172/JCI28568.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505(7483):327–34.  https://doi.org/10.1038/nature12984.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shiozawa Y, Eber MR, Berry JE, Taichman RS. Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. Bonekey Rep. 2015;4:689.  https://doi.org/10.1038/bonekey.2015.57.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121(4):1298–312.  https://doi.org/10.1172/JCI43414.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wang H, Yu C, Gao X, Welte T, Muscarella AM, Tian L, et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015;27(2):193–210.  https://doi.org/10.1016/j.ccell.2014.11.017.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62(6):1832–7.PubMedGoogle Scholar
  26. 26.
    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.  https://doi.org/10.1038/35102167.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6.  https://doi.org/10.1038/35065016.CrossRefPubMedGoogle Scholar
  28. 28.
    Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977–88.  https://doi.org/10.1016/j.immuni.2006.10.016.CrossRefPubMedGoogle Scholar
  29. 29.
    Blank U, Karlsson S. TGF-beta signaling in the control of hematopoietic stem cells. Blood. 2015;125(23):3542–50.  https://doi.org/10.1182/blood-2014-12-618090.CrossRefPubMedGoogle Scholar
  30. 30.
    Yumoto K, Eber MR, Wang J, Cackowski FC, Decker AM, Lee E, et al. Axl is required for TGF-beta2-induced dormancy of prostate cancer cells in the bone marrow. Sci Rep. 2016;6:36520.  https://doi.org/10.1038/srep36520.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Decker AM, Jung Y, Cackowski F, Taichman RS. The role of hematopoietic stem cell niche in prostate cancer bone metastasis. J Bone Oncol. 2016;5(3):117–20.  https://doi.org/10.1016/j.jbo.2016.02.005.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Johnson RW, Finger EC, Olcina MM, Vilalta M, Aguilera T, Miao Y, et al. Erratum: induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 2016;18(11):1260.  https://doi.org/10.1038/ncb3433.CrossRefPubMedGoogle Scholar
  33. 33.
    Sosnoski DM, Norgard RJ, Grove CD, Foster SJ, Mastro AM. Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment. Clin Exp Metastasis. 2015;32(4):335–44.  https://doi.org/10.1007/s10585-015-9710-9.CrossRefPubMedGoogle Scholar
  34. 34.
    Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:8983.  https://doi.org/10.1038/ncomms9983.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Yumoto K, Berry JE, Taichman RS, Shiozawa Y. A novel method for monitoring tumor proliferation in vivo using fluorescent dye DiD. Cytometry A. 2014;85(6):548–55.  https://doi.org/10.1002/cyto.a.22434.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Cammarota F, Laukkanen MO. Mesenchymal stem/stromal cells in stromal evolution and Cancer progression. Stem Cells Int. 2016;2016:4824573.  https://doi.org/10.1155/2016/4824573.CrossRefPubMedGoogle Scholar
  37. 37.
    Shi Y, Du L, Lin L, Wang Y. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16(1):35–52.  https://doi.org/10.1038/nrd.2016.193.CrossRefPubMedGoogle Scholar
  38. 38.
    • Vallabhaneni KC, Penfornis P, Xing F, Hassler Y, Adams KV, Mo YY, et al. Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway. Oncotarget. 2017;8(66):109861–76.  https://doi.org/10.18632/oncotarget.22371. Paper shows that a subpopulation of breast cancer cells are susceptible to extracellular vesicle induced dormancy. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    •• Lopes-Bastos B, Jin L, Ruge F, Owen S, Sanders A, Cogle C, et al. Association of breast carcinoma growth with a non-canonical axis of IFNgamma/IDO1/TSP1. Oncotarget. 2017;8(49):85024–39.  https://doi.org/10.18632/oncotarget.18781. Paper introduces a new mechanism for IFNγ to regulate dormancy. CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Young GD, Murphy-Ullrich JE. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem. 2004;279(46):47633–42.  https://doi.org/10.1074/jbc.M404918200.CrossRefPubMedGoogle Scholar
  41. 41.
    Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011;208(13):2641–55.  https://doi.org/10.1084/jem.20110840.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Sharma S, Xing F, Liu Y, Wu K, Said N, Pochampally R, et al. Secreted protein acidic and rich in cysteine (SPARC) mediates metastatic dormancy of prostate Cancer in bone. J Biol Chem. 2016;291(37):19351–63.  https://doi.org/10.1074/jbc.M116.737379.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Hurst RE, Bastian A, Bailey-Downs L, Ihnat MA. Targeting dormant micrometastases: rationale, evidence to date and clinical implications. Ther Adv Med Oncol. 2016;8(2):126–37.  https://doi.org/10.1177/1758834015624277.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ghajar CM. Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 2015;15(4):238–47.  https://doi.org/10.1038/nrc3910.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Manjili MH. The inherent premise of immunotherapy for cancer dormancy. Cancer Res. 2014;74(23):6745–9.  https://doi.org/10.1158/0008-5472.CAN-14-2440.CrossRefPubMedGoogle Scholar
  46. 46.
    Price TT, Burness ML, Sivan A, Warner MJ, Cheng R, Lee CH, et al. Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med. 2016;8(340):340ra373.  https://doi.org/10.1126/scitranslmed.aad4059.CrossRefGoogle Scholar
  47. 47.
    Cho BS, Kim HJ, Konopleva M. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J Intern Med. 2017;32(2):248–57.  https://doi.org/10.3904/kjim.2016.244.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, et al. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER(+) breast cancer. Nat Cell Biol. 2018;20(2):211–21.  https://doi.org/10.1038/s41556-017-0021-z.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • D. Brooke Widner
    • 1
  • Sun H. Park
    • 1
  • Matthew R. Eber
    • 1
  • Yusuke Shiozawa
    • 1
    Email author
  1. 1.Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of MedicineWinston-SalemUSA

Personalised recommendations